Skip to main content

Development of novel antiviral drugs against Influenza

Objective

Influenza viruses cause a highly contagious respiratory disease in both humans and animals. Typically, influenza spreads worldwide in seasonal epidemics resulting in an estimated 3 to 5 million cases of severe illness and 250,000 to 500,000 deaths annually. In addition to these seasonal epidemics there have been several pandemics since the early 1900’s, where highly virulent strains emerged, the most devastating being the ‘Spanish Flu’ of 1918, which caused 20-40 million deaths globally. Vaccination is currently the primary means of controlling the spread of influenza virus infections but due to the virus’s notorious ability to mutate, new vaccines must be developed each year. There are a few antiviral drugs that are currently on the market; however, their therapeutic potential is restricted through rapid appearance of drug-resistant viruses during treatment. Thus, the need for novel effective drugs against influenza is evident. The FLUCURE project aims at developing innovative, first-in-class therapeutics against influenza by targeting the viral ribonucleoprotein complex, which is replication core of the virion and a major contributor to viral virulence. The high level of conservation combined with slow mutation rates of the ribonucleoprotein complex should result in therapeutics with broad viral strain specificity associated with a reduced risk for developing resistance. FLUCURE builds further on two successful EU-FP7 drug discovery projects, FLUINHIBIT and FluDrugStrategy, both targeting specific but different protein-protein interactions of the viral ribonucleoprotein complex with small molecule inhibitors. A consortium of 10 partners with the required complementary skills will progress the lead candidates from these two projects synergistically through lead optimization and preclinical development phases, with the final objective to deliver one or more drug candidates suitable for entering clinical development within 4 years.

Call for proposal

FP7-INFLUENZA-2010
See other projects for this call

Coordinator

VIRONOVA AB
Address
Gavlegatan 22
113 30 Stockholm
Sweden

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Charlotta Hjerpe (Dr.)
EU contribution
€ 1 247 200

Participants (9)

BEACTICA THERAPEUTICS AB
Sweden
EU contribution
€ 707 600
Address
Virdings Alle 2
754 50 Uppsala

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Per Kaellblad (Dr.)
PIKE PHARMA GMBH
Switzerland
EU contribution
€ 1 383 000
Address
Technoparkstrasse 1
CH-8005 Zuerich

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ulrich Kessler (Dr.)
UNIVERSITAETSKLINIKUM FREIBURG
Germany
EU contribution
€ 771 000
Address
Hugstetter Strasse 49
79106 Freiburg

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Juergen Dreyer (Mr.)
INSTITUTE OF ORGANIC CHEMISTRY WITH CENTRE OF PHYTOCHEMISTRY - BULGARIAN ACADEMY OF SCIENCES
Bulgaria
EU contribution
€ 208 800
Address
Ul. Academic Georgi Bonchev Bld 9
1113 Sofia

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Lilia Viteva (Dr.)
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

Participation ended

Netherlands
EU contribution
€ 803 400
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Yvonne Kops (Ms.)
VILNIAUS UNIVERSITETAS
Lithuania
EU contribution
€ 192 000
Address
Universiteto G. 3
01513 Vilnius

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Vida Lapinskaite (Ms.)
PHARMACELSUS GMBH
Germany
EU contribution
€ 393 600
Address
Science Park 2
66123 Saarbrucken

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Reiner Class (Dr.)
UNIVERSITA DEGLI STUDI DI SIENA
Italy
EU contribution
€ 276 000
Address
Via Banchi Di Sotto 55
53100 Siena

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Maurizio Botta (Prof.)
STICHTING VU
Netherlands
Address
De Boelelaan 1105
1081 HV Amsterdam

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Yvonne Kops (Dr.)